Article
Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901).
Future oncology (London, England) - 1 Feb 2022
Okuma Yusuke, Shimokawa Mototsugu, Hashimoto Kana, Mizutani Hideaki, Wakui Hiroshi, Murakami Shuji, Atagi Shinji, Minato Koichi, Seike Masahiro, Ohe Yuichiro, Kubota Kaoru
Abstract excerpt
Patients with uncommon EGFR-mutated non-small-cell lung cancer (NSCLC) demonstrated lower clinical efficacy of first-generation EGFR-tyrosine kinase inhibitors compared with patients harboring common EGFR-mutated NSCLC. The US FDA has approved afatinib for uncommon EGFR mutation positive NSCLC based on the pooled analysis in the first- or second-line setting. Osimertinib has limited evidence in the small sample...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.